Pfizer gene therapy for Duchenne fails to meet goals of key trial
Pfizer’s experimental gene therapy for Duchenne muscular dystrophy didn’t improve the motor function of young boys enrolled in a late-stage
July 5, 2024
Pfizer’s experimental gene therapy for Duchenne muscular dystrophy didn’t improve the motor function of young boys enrolled in a late-stage
Foresite Capital, an investment firm that backs life sciences and healthcare companies, has raised a $900 million fund. The fund,
Approval of Eli Lilly’s experimental Alzheimer’s disease drug donanemab would help drive sales of Eisai and Biogen’s rival medicine Leqembi,
Dive Brief: Moderna on Monday said a combination flu and COVID-19 shot it’s developing met the goal of a late-stage
An experimental and closely watched medicine for Alzheimer’s disease is one step closer to approval, after receiving support from a
As healthcare moves toward the shared goal of improving patient care more economically, stakeholders across the healthcare ecosystem are increasingly
Dive Brief: Seres Therapeutics plans to sell all the rights to its microbiome pill to Nestlé Health Science as it
A group of advisers to the Food and Drug Administration on Wednesday unanimously recommended that COVID-19 vaccines be updated to
After a turbulent few years, 2024 has given the biotechnology industry some signs of a return to normalcy. For one,
Today, several brief updates from BioPharma Dive Reporter Gwendolyn Wu, who spent this week attending BIO’s annual meeting in San